coronary artery disease
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) patients with successful BP-DES implantation as well as no major adverse events (death, new onset AMI, stroke, major bleeding) during hospitalization 2) Patients who can continue DAPT of aspirin and P2Y12 receptor antagonist 3) Patients with completed informed consent
Exclusion criteria
Exclusion criteria: 1) patients requiring oral anticoagulant 2) patients with previous history of stent thrombosis 3)patients treated with any stents except BP-DES 4) patients known to have intolerance of P2Y12 receptor antagonist 5) patients requiring other antiplatelet agents except aspirin and P2Y12 inhibitor 6) patients who have cancer with life expectancy shorter than 2 years 7) pregnant or antcipated pregnant woman 8) patients implanted bioresorbable scaffold within 3 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite endpointof cardiovascular death, stroke, stent thrombosis, clinically significant bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular death/ MI/ stroke/ definite ST at 12 months Major bleeding (TIMI Major/ Minor) at 12 months | — |
Countries
Japan
Contacts
Iwate Medical University Hospital Division of Cardiology, Department of Internal Medicine